Medexus Pharmaceuticals is set to report its fiscal Q4 2026 results on July 2, 2026, with analysts expecting a modest EPS of CA$0.01. Investors will be keen to see if the company can maintain momentum after recent positive news on GRAFAPEX.
On July 2, 2026, Medexus Pharmaceuticals Inc (MDP.TO) will release its earnings for the fourth quarter of fiscal 2026, following a fiscal period that ended on June 30. With an EPS estimate of CA$0.01, the market will be watching closely to see if the company can turn around its recent losses and capitalize on its growth in the oncology market.
Investor takeaway: Long-term investors should watch for signs of profitability and continued product performance as Medexus navigates its growth strategies.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Earnings Preview: Can Medexus Turn the Corner?
With an EPS estimate of CA$0.01, Medexus Pharmaceuticals Inc is under pressure to demonstrate a recovery from its recent losses. This earnings report will be crucial for assessing the company's ability to leverage its product pipeline and improve its financial standing, especially after a year marked by significant fluctuations in its stock price.
Advertisement
Bull case
- Growth Potential: Medexus has shown strong performance with GRAFAPEX (treosulfan) for Injection, which could lead to better financial results.
- Market Cap Opportunity: With a market cap of CA$142.16M and a forward P/E of 16.86x, there’s room for growth if earnings meet or exceed expectations.
- Recent Developments: The recent licensing deal for UM171 Cell Therapy may create new revenue streams and strengthen the company's portfolio.
Bear case
- Negative Profit Margin: Medexus currently has a profit margin of -2.41%, highlighting ongoing challenges in achieving profitability.
- Market Sentiment: Investors may be cautious due to the company's history of losses, with a TTM EPS of CA$-0.10.
- Volatility: The stock has fluctuated between CA$2.47 and CA$5.10 over the past year, indicating potential volatility that could affect investor sentiment.
Medexus Pharmaceuticals Inc (MDP.TO)
Overview: Medexus Pharmaceuticals Inc focuses on developing and commercializing innovative pharmaceutical products, particularly in oncology. What the screen shows: The company has a market cap of CA$142.16M, with a forward P/E of 16.86x and an EPS estimate of CA$0.01 for the upcoming earnings report. Risks and watch items: Investors should be aware of the company's negative profit margin of -2.41% and the volatility in its stock price, which has ranged from CA$2.47 to CA$5.10 over the past year. For more details, visit Medexus Pharmaceuticals Inc.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
